300 related articles for article (PubMed ID: 11797767)
1. Prospects for development of a vaccine against the West Nile virus.
Monath TP
Ann N Y Acad Sci; 2001 Dec; 951():1-12. PubMed ID: 11797767
[TBL] [Abstract][Full Text] [Related]
2. West Nile virus vaccine.
Monath TP; Arroyo J; Miller C; Guirakhoo F
Curr Drug Targets Infect Disord; 2001 May; 1(1):37-50. PubMed ID: 12455232
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
[TBL] [Abstract][Full Text] [Related]
4. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes.
Johnson BW; Chambers TV; Crabtree MB; Arroyo J; Monath TP; Miller BR
Med Vet Entomol; 2003 Sep; 17(3):235-43. PubMed ID: 12941006
[TBL] [Abstract][Full Text] [Related]
5. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
6. Yellow fever vector live-virus vaccines: West Nile virus vaccine development.
Arroyo J; Miller CA; Catalan J; Monath TP
Trends Mol Med; 2001 Aug; 7(8):350-4. PubMed ID: 11516995
[TBL] [Abstract][Full Text] [Related]
7. ChimeriVax-West Nile vaccine.
Hall RA; Khromykh AA
Curr Opin Mol Ther; 2007 Oct; 9(5):498-504. PubMed ID: 17932814
[TBL] [Abstract][Full Text] [Related]
8. A live, attenuated recombinant West Nile virus vaccine.
Monath TP; Liu J; Kanesa-Thasan N; Myers GA; Nichols R; Deary A; McCarthy K; Johnson C; Ermak T; Shin S; Arroyo J; Guirakhoo F; Kennedy JS; Ennis FA; Green S; Bedford P
Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6694-9. PubMed ID: 16617103
[TBL] [Abstract][Full Text] [Related]
9. West Nile virus vaccines.
Hall RA; Khromykh AA
Expert Opin Biol Ther; 2004 Aug; 4(8):1295-305. PubMed ID: 15268663
[TBL] [Abstract][Full Text] [Related]
10. Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines.
Kanesa-Thasan N; Putnak JR; Mangiafico JA; Saluzzo JE; Ludwig GV
Am J Trop Med Hyg; 2002 Feb; 66(2):115-6. PubMed ID: 12135278
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.
Dayan GH; Pugachev K; Bevilacqua J; Lang J; Monath TP
Viruses; 2013 Dec; 5(12):3048-70. PubMed ID: 24351795
[TBL] [Abstract][Full Text] [Related]
12. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.
Arroyo J; Miller C; Catalan J; Myers GA; Ratterree MS; Trent DW; Monath TP
J Virol; 2004 Nov; 78(22):12497-507. PubMed ID: 15507637
[TBL] [Abstract][Full Text] [Related]
13. Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.
Quintel BK; Thomas A; Poer DeRaad DE; Slifka MK; Amanna IJ
Vaccine; 2019 Jul; 37(30):4214-4221. PubMed ID: 30606462
[TBL] [Abstract][Full Text] [Related]
14. Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus).
Langevin SA; Arroyo J; Monath TP; Komar N
Am J Trop Med Hyg; 2003 Jul; 69(1):78-80. PubMed ID: 12932102
[TBL] [Abstract][Full Text] [Related]
15. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
[TBL] [Abstract][Full Text] [Related]
16. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.
Li XF; Zhao W; Lin F; Ye Q; Wang HJ; Yang D; Li SH; Zhao H; Xu YP; Ma J; Deng YQ; Zhang Y; Qin ED; Qin CF
J Gen Virol; 2013 Dec; 94(Pt 12):2700-2709. PubMed ID: 24092759
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.
Seino KK; Long MT; Gibbs EP; Bowen RA; Beachboard SE; Humphrey PP; Dixon MA; Bourgeois MA
Clin Vaccine Immunol; 2007 Nov; 14(11):1465-71. PubMed ID: 17687109
[TBL] [Abstract][Full Text] [Related]
18. Non-structural protein 1 (NS1) antibody-based assays to differentiate West Nile (WN) virus from Japanese encephalitis virus infections in horses: effects of WN virus NS1 antibodies induced by inactivated WN vaccine.
Kitai Y; Kondo T; Konishi E
J Virol Methods; 2011 Jan; 171(1):123-8. PubMed ID: 20974180
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model.
Tesh RB; Arroyo J; Travassos Da Rosa AP; Guzman H; Xiao SY; Monath TP
Emerg Infect Dis; 2002 Dec; 8(12):1392-7. PubMed ID: 12498653
[TBL] [Abstract][Full Text] [Related]
20. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available.
Ishikawa T; Yamanaka A; Konishi E
Vaccine; 2014 Mar; 32(12):1326-37. PubMed ID: 24486372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
